Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.47 |
| ▸ | RARA | P10276 | 4/20 | 0.47 |
| ▸ | RARG | P13631 | 10/20 | 0.36 |
| ▸ | RARB | P10826 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033010 | 0.91 | IKBKB (0.48) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL6033341 | 0.82 | IKBKB (0.49) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL6033250 | 0.81 | IKBKB (0.52) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL8397886 | 0.81 | RARA (0.66) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL8620249 | 0.81 | IKBKB (0.48) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL8397932 | 0.81 | IKBKB (0.48) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL8394251 | 0.80 | IKBKB (0.56) | IKBKBRARARARGRARBGPR55 | |
| SCHEMBL8394320 | 0.79 | RARA (0.58) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL8399153 | 0.79 | IKBKB (0.58) | IKBKBRARARARGRARBKMT2A | |
| SCHEMBL7753722 | 0.79 | RARA (0.53) | IKBKBRARARARGRARBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-6921777-B2 | Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-26 | — | — | US | disclosed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | disclosed |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-01-16 | — | — | US | disclosed |
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | disclosed |
| EP-0986537-B1 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-08-07 | — | — | EP | disclosed |
| EP-1086080-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2001-03-28 | — | — | EP | disclosed |
| EP-0986537-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development, S.N.C. (FR) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999065872-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999050239-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | TYR, CYP1B1, MITF | IKBKB 4108/4885RARA 1792/4885RARG 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.